Metformin reduces the stimulatory effect of obesity on in vivo Walker-256 tumor development and increases the area of tumor necrosis  by Fonseca, Eveline Aparecida Isquierdo et al.
Life Sciences 88 (2011) 846–852
Contents lists available at ScienceDirect
Life Sciences
j ourna l homepage: www.e lsev ie r.com/ locate / l i fesc ieMetformin reduces the stimulatory effect of obesity on in vivo Walker-256 tumor
development and increases the area of tumor necrosis
Eveline Aparecida Isquierdo Fonseca a, Maria Aparecida de Oliveira a, Núbia de Souza Lobato a,
Eliana Hiromi Akamine a, Alison Colquhoun b, Maria Helena Catelli de Carvalho a,
Szulim Ber Zyngier a, Zuleica Bruno Fortes a,⁎
a Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
b Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil⁎ Corresponding author at: Department of Pharmac
Sciences, University of São Paulo, São Paulo, 05508–900
7317.
E-mail address: zbfortes@icb.usp.br (Z.B. Fortes).
0024-3205 © 2011 Elsevier Inc.
doi:10.1016/j.lfs.2011.03.005
Open access under the Ela b s t r a c ta r t i c l e i n f oArticle history:
Received 9 November 2010
Accepted 3 March 2011
Keywords:
Metformin
Obesity
Insulin resistance
Cancer
Tumor necrosis
Aims: The objective of this study was to analyze the inﬂuence of obesity and insulin resistance on tumor
development and, in turn, the effect of insulin sensitizing agents.
Main methods: Male offspring of Wistar rats received monosodium glutamate (400 mg/kg) (obese) or saline
(control) from the second to sixth day after birth. Sixteen-week-old control and obese rats received 5×105
Walker-256 tumor cells, subcutaneously injected into the right ﬂank. Some of the obese and control rats
received concomitant treatment with metformin (300 mg/kg) by gavage. At the 18th week, obesity was
characterized. The percentage of rats that developed tumors, the tumor relative weight and the percentage of
cachexia incidence were analyzed. The tumor tissue was evaluated histologically by means of hematoxylin
and eosin staining.
Key ﬁndings: Metformin did not correct the insulin resistance in obese rats. The tumor development was
signiﬁcantly higher in the obese group, whereas metformin treatment reduced it. After pathological analysis,
we observed that the tumor tissues were similar in all groups except for adipocytes, which were found in
greater quantity in the obese and metformin-treated obese groups. The area of tumor necrosis was higher in
the group treated with metformin when compared with the untreated one.
Signiﬁcance: Metformin reduced Walker-256 tumor development but not cachexia in obese rats. The
reduction occurred independently of the correction of insulin resistance. Metformin increased the area of
necrosis in tumor tissues, which may have contributed to the reduced tumor development.
© 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
The prevalence of excess weight and obesity in most developed
countries has been increasing markedly over the past two decades,
and the association between obesity and other chronic diseases is also
increasing (Hill 2006; Zimmet et al., 2001).
Epidemiological studies have associated obesity with a wide
variety of cancers (Calle and Kaaks, 2004; Giovannucci and Michaud,
2007; Hursting et al., 2007; Jee et al., 2005). The insulin resistance,
hyperinsulinemia, oxidative stress and chronic inﬂammation often
present in obesity can be the mechanisms by which obesity induces
or promotes tumorigenesis (Hursting et al., 2007). In fact, chronic
hyperinsulinemia has been associated with cancers of the colon, breast,
pancreas, and endometrium (Calle and Kaaks, 2004; Giovannucci and
Michaud, 2007). These tumorigenic effects of insulin may be directlyology, Institute of Biomedical
, Brazil. Tel./fax: +55 11 3091
sevier OA license.mediated by insulin receptors in the (pre)neoplastic cells, or they
might be due to related changes in endogenous hormone metabolism
(Calle and Kaaks, 2004). Insulin promotes the synthesis and biological
activity of insulin-like growth factor 1 (IGF-1), and both can stimulate
cell proliferation contributing to greater tumor development in obesity
(Calle and Kaaks, 2004; Pollak, 2007).
Metformin, an antidiabetic drug, can have a direct antitumoral
effect or can act indirectly to improve insulin sensitivity (Evans et al.,
2007; Pollak, 2007; Schneider et al., 2001). Metformin lowers the
elevated insulin levels found in type 2 diabetes by inhibiting gluco-
neogenesis and hepatic glucose output, which in turn reduces blood
glucose levels and thus decreases insulin levels. Metformin stimulates
glucose uptake by muscle and adipose tissue by activation of AMP-
activated protein kinase (AMPK) and can activate the same LKB1/
AMPK pathway in cancer cells in vitro (Algire et al., 2008; Ropelle
et al., 2007; Zakikhani et al., 2006). In these cells, the consequences
include reduced signaling at mTOR and growth inhibition (Algire
et al., 2008; Zakikhani et al., 2006). Thus, although it is already known
that obesity increases the risk of developing cancer and that met-
formin may have an antitumor effect in this condition, further studies
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cancer and the effect of metformin on it. Therefore, we investigated
the inﬂuence of experimental obesity on tumor development and the
effect of in vivo metformin treatment to better understand the rela-
tionship of tumor development and obesity and the inﬂuence on it
of insulin-sensitizing agents. For this we used the MSG model of
obesity in rats and Walker-256 tumor cells. We analyzed tumor
development, the cachexia incidence and the effect of metformin on
these parameters.
Materials and methods
Animals and induction of obesity
Male offspring of Wistar rats from our own breeding colony
received daily subcutaneous injections of monosodium glutamate—
MSG (400 mg/kg body weight; Sigma-Aldrich, Germany) dissolved in
0.9% NaCl from the second to sixth days after birth. Control littermates
received an equivalent volume of the vehicle (Fig. 1). The rats were
weaned on the 21st day and were kept in standard cages under
controlled light (12-h light/dark phase) and temperature conditions
(22±1 °C), with free access to food and water.
The experimental procedures were approved by the Ethical Com-
mittee for Animal Research of the Institute of Biomedical Sciences,
University of São Paulo, Brazil (Protocol n°007/04).
Tumor xenograft model and metformin treatment
In 16-week-old control (C) and obese-MSG (O) rats, 5×105Walker-
256 tumor cells were inoculated s.c. in the right ﬂank. These rats were
randomized to four groups: control tumor (CT), control tumor metfor-
min (CTM), obese-MSG tumor (OT) and obese-MSG tumor metformin
(OTM). The treatment with metformin (Glifage, Merck, Brazil) started
on the same day that tumor cells were inoculated. The CTM and OTM
rats received a dose of 300 mg/kg body weight of metformin by gavage
for 15 days (Fig. 1).
Characterization of obesity and analysis of metabolic parameters
On the day of the experiment, after 5 h of food deprivation, the rats
in all the groups were weighed and blood samples were taken from
the descending aorta under sodium thiopental anesthesia (50 mg/kg,
intraperitoneally, Cristália, Brazil). The blood samples were kept atFig. 1. Schematic representation of the experimental procedures. Male offspring of
Wistar rats received daily subcutaneous injections of monosodium glutamate—MSG
(400 mg/kg bodyweight; Sigma-Aldrich, Germany) (obese) or 0.9% NaCl (control) from
the second to sixth day after birth. At the 16th week control and obese rats received
5×105 Walker-256 tumor cells, s.c. injected into the right ﬂank. The treatment with
metformin (300 mg/kg bw, by gavage, for 15 days) started on the same day that tumor
cells were inoculated. CT, control tumor; CTM, control tumor metformin; OT, obese-
MSG tumor and OTM, obese-MSG tumor metformin.room temperature for half an hour to coagulate, followed by centri-
fugation at 1900×g and 20 °C. The serum isolated was frozen at
−80 °C for assessment of biochemical parameters. Glucose levels and
the lipid proﬁle were assessed spectrophotometrically using speciﬁc
commercial kits (colorimetric method, Celm, Brazil). Insulin concen-
tration was determined using a rat-speciﬁc radioimmunoassay kit
(Linco, USA). The Lee index was calculated as follows: body weight1/3
(g)/nasal-anal length (cm)×100. The white adipose tissue (periepi-
didymal and retroperitoneal) and the lean mass (soleus, extensor
digitorum longus (EDL) and gastrocnemius muscle) were weighed.
The lipid peroxidation rate was determined using the thiobarbituric
acid reactive substance (TBARS) assay. To assess the serum insulin
levels, it was necessary to add two groups: control without tumor and
obese-MSG without tumor.
Intravenous insulin tolerance test (ITT)
Tail blood samples were collected before and 4, 8, 12 and 16 min
after an intravenous injection of regular insulin (0.75 U/kg bw,
Biobras, Brazil). The constant rate for blood glucose disappearance
during the test (kITT) was calculated based on the linear regression of
the neperian logarithm of glucose concentrations. Blood glucose
concentration was measured using a Glucometer and glucose strips
(Advantage®, Roche, Brazil).
Intravenous glucose tolerance test (GTT)
This test was performed at noon on the 18th week of age of the
animals. Tail blood samples were collected before and 5, 10, 20, 30 and
60 min after an intravenous injection of glucose (0.75 g/kg bw). Blood
glucose concentration was measured using a Glucometer and glucose
strips (Advantage®, Roche, Brazil).
Analysis of food intake
To assess food intake, it was necessary to add two groups: control
without tumor and obese-MSG without tumor. The food intake was
calculated and represented as the average food intake for 3 conse-
cutive days at the 18th week of age of animals.
Tumor evaluation
At the 18th week of age, tumor weight (g/100 g body weight) and
tumor volume (cm3/100 g body weight) were evaluated. Tumor
volume was calculated using the formula (0.5×a×(b2)) (where a is
the larger diameter and b is the smaller diameter) with an electronic
caliper as described previously (Kato et al., 1994). The percentage of
rats that were inoculated with and developed the tumor was also
calculated.
Histological analysis
After ﬁxation with paraformaldehyde (4%) for 24 h, the tumor
tissues were subjected to processing, during which they were dehy-
drated with increasing concentrations of alcohol (alcohol 70, 85, 95
and 100%), diaphanized, bathed in xylene and embedded in Paraplast
(Paraplast X-tra, SEM). They were then cut into sections with a rotary
microtome. The 6 μm thick sections were mounted on slides and
stained with hematoxylin–eosin (H & E).
The slides were analyzed with a optical microscope (AXIOSKOP
Zeiss, Germany) using a 10× and 20× objective for the overall assess-
ment of tumor tissue. They were then photographed using an analog
camera (Samsung, SHC-410 NAD, Korea). Quantitative analysis of
slides was performed using the program ImageJ.
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viable tumor cells (proliferating cells), cells in necrosis or apoptosis,
adipocytes and blood vessels was performed.
Cachexia incidence
Loss of body mass (LBM) was calculated as follows:
LBM %ð Þ = 100 × BMi–BMf + MT + GBMð Þ= BMi + GBMð Þ;
where BMi: initial body mass of a rat with tumor (g); BMf: ﬁnal body
mass of a ratwith tumor (g);MT: tumormass (g); and GBM: bodymass
gain of a rat without tumor during the 15 days of the experiment (g).
The rats were considered cachectic when the LBMwas higher than
10%. The cachexia incidence corresponds to the percentage of rats that
became cachectic.
Data analysis
Data are given as mean±SEM and n denotes the number of animals
used.Datawereanalyzedusing theStudent's t-test for comparisonof two
groupsor one-wayANOVAfollowedbyTukey's post-hoc test formultiple
comparisons. P values less than 0.05 were considered signiﬁcant.
Results
Characterization of obesity and analysis of metabolic parameters
The Lee index and the periepididymal and retroperitoneal adipose
tissue weights were higher in the OT group than in the CT group. The
lean mass (soleus and EDL muscle) weight of the OT group was not
signiﬁcantly different from that of CT, but the gastrocnemius muscle
was signiﬁcantly smaller in the OT group. In addition, serum tri-
glycerides and very low density lipoprotein (VLDL) cholesterol, but
not total cholesterol levels, were higher in the OT group than in the CT
group. Lipid peroxidation rate was signiﬁcantly higher in the OT
group. Serum glucose levels were similar in all groups (Table 1).
Metformin did correct the dyslipidemia and reduced the periepididy-
mal and retroperitoneal adipose tissue weight as well as the lipid peroxi-
dation rate. Weight loss was signiﬁcantly higher in the OT group than in
the CT group (Table 1), but metformin did not correct this parameter.Table 1
Biological parameters of the animals.
CT
Initial weight (g) 386.2±7.2
Final weight (g) 384.0±9.5
Carcass weight (g) 362.5±9.8
Weight loss (g) 22.2±3.8
Lee index (×100) 29.6±0.2
Periepididymal adipose tissue (g/100 g bw) 1.3±0.1
Retroperitoneal adipose tissue (g/100 g bw) 1.2±0.1
Soleus muscle (g/100 g bw) 0.041±0.002
EDL muscle (g/100 g bw) 0.041±0.001
Gastrocnemius muscle
(g/100 g bw)
0.509±0.012
Glucose (mg/dL) 94.2±6.2
Total cholesterol (mg/dL) 48.6±3.5
Triglycerides (mg/dL) 109.5±22.7
HDL-cholesterol (mg/dL) 5.8±0.5
LDL-cholesterol (mg/dL) 27.8±3.8
VLDL-cholesterol (mg/dL) 23.8±4.7
Serum TBARS (nmol/L) 0.15±0.03
Control tumor (CT), control tumor metformin (CTM), obese-MSG tumor (OT) and obese-M
⁎⁎⁎ pb0.0001 vs CT.
⁎ pb0.05 vs CT.
⁎⁎ pb0.05 vs CT.
# pb0.05 vs OT.Obese rats without tumors had higher serum levels of insulin than
obese rats with tumors. The presence of a tumor reduced insulin levels
in both CT and OT groups. Metformin did not alter the already reduced
insulin levels in these latter groups (Fig. 2).
The constant rate for blood glucose disappearance during the kITT
test obtained after insulin overload was signiﬁcantly smaller in the OT
rats when compared to the CT rats, indicating insulin resistance in
these rats. Metformin did not correct this parameter (Fig. 3A and B).
The basal glucose levels (T0) (before the i.v. injection of 0.75 mg/
kg glucose) was not different between groups. The peak glucose
occurred 5 min after the glucose load, with a decline in levels after this
time (T5). The area under the glucose concentration curve in blood
was signiﬁcantly higher in the OT group, showing glucose intolerance.
Metformin did not correct this parameter (Fig. 3C and D).Analysis of food intake
The food intake was signiﬁcantly lower in the groups with tumor
(CT, CTM, OT and OTM) when compared with their respective groups
without tumor. Metformin reduced the food intake only in the OTM
group (Fig. 4).Analysis of tumor development and percentage of rats that developed
tumors
Tumor development and the percentage of rats that developed
tumors were signiﬁcantly higher in the OT group when compared
with the CT group. Both parameters were reduced by metformin
treatment (Fig. 5). After pathological analysis, we observed that the
tumor tissues were similar in all groups except for adipocytes, which
were found in greater quantity in the OT and OTM groups (Fig. 6). The
area of tumor necrosis was higher in groups treated with metformin
when compared with the other groups (CT 33.1 vs CTM 52.6*, OT 34.2
vs OTM 58.7* %, n=10, *pb0.05).Cachexia incidence
The cachexia incidence was higher in the OT group than in the
other groups; metformin did not correct this parameter (OT 90*** vs.
CT 50, CTM 50, OTM 100%, n=18, ***pb0.0001).CTM OT OTM
370.5±7.0 316.3±8.3⁎ 337.8±7.0
355.0±6.7 305.1±9.0⁎⁎⁎ 318.5±8.1
338.3±7.4 286.2±9.3⁎⁎⁎ 302.1±9.3
39.6±4.8 41.1±5.0⁎ 40.1±4.7
29.3±0.2 31.3±0.3⁎⁎⁎ 30.9 ±0.2⁎⁎⁎
1.0±0.1⁎⁎ 2.5±0.1⁎⁎⁎ 2.1±0.1#
0.6±0.1⁎⁎ 2.7±0.1⁎⁎⁎ 2.1±0.1#
0.047±0.002 0.040±0.002 0.041±0.003
0.043±0.002 0.039±0.003 0.040±0.002
0.537±0.020 0.407±0.020⁎⁎⁎ 0.451±0.010
97.7±5.0 90.4±4.7 99.4±4.0
53.1±3.1 56.5±4.3 56.7±3.8
60.7±12.1 215.5±26.1⁎⁎ 124.3±22.2#
6.9±0.7 6.1±0.6 9.3±0.7#
35.1±3.2 23.1±2.0 25.9±3.2
15.6±2.5 45.2±5.1⁎⁎ 27.5±4.7#
0.20±0.03 0.40±0.03⁎⁎⁎ 0.27±0.03#
SG tumor metformin (OTM) (n=10 for each experimental group).
Fig. 2. Effects ofMSG and/ormetformin treatment and inoculation ofWalker-256 tumor
cells on serum insulin levels (in ng/mL). CWT, controlwithout tumor; CT, control tumor;
CTM, control tumormetformin; OWT, obese-MSGwithout tumor; OT, obese-MSG tumor
and OTM, obese-MSG tumor metformin. Data are expressed as mean±SEM. *pb0.05 vs
CWT and ***pb0.0001 vs OT. Numbers inside the bars represent the number of rats used.
Fig. 4. Effects ofMSG and/ormetformin treatment and inoculation ofWalker-256 tumor
cells on food intake (g/100 g body weight) represented by average food intake in 3
consecutive days at 18 weeks of age of rats. CWT, control without tumor; CT, control
tumor; CTM, control tumor metformin; OWT, obese-MSG without tumor; OT, obese-
MSG tumor and OTM, obese-MSG tumormetformin. Data are expressed asmean±SEM.
**pb0.05 vs CWT, ***pb0.0001 vs OWT and *pb0.05 vs OT. Numbers inside the bars
represent the number of rats used.
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Epidemiological studies have associated obesity with a wide variety
of cancers (Calle and Kaaks, 2004; Giovannucci and Michaud, 2007;
Hursting et al., 2007; Jee et al., 2005) and recent data suggest that
metformin can have a direct antitumoral effect or can act indirectly by
improving insulin sensitivity (Evans et al., 2007; Pollak, 2007; Schneider
et al., 2001). Here we show that metformin reduces the stimulatory
effect of obesity on in vivo Walker-256 tumor development and
increases the area of tumor necrosis.
The Walker-256 tumor we used is a breast carcinosarcoma often
used in studies of anticancer therapies and tumor-induced cachexiaFig. 3. (A) Glycemic curve after insulin overload, (B) the constant rate for blood glucose disa
under the curve from GTT. CT, control tumor; CTM, control tumor metformin; OT, obese-M
*pb0.05 vs CT. Numbers inside the bars represent the number of rats used.(Fernandes et al., 1990; Folador et al., 2009); it is speciﬁc to rats and
easily transplanted.
Our study is the ﬁrst to show that obesity increases tumor de-
velopment, the number of rats that develop tumors and neoplastic
cachexia incidence. Insulin resistance, the metabolic changes and the
increased generation of reactive oxygen species (ROS), assessed indi-
rectly by the lipid peroxidation rate,may contribute to these alterations.
High concentrations of diverse free radicals and oxidants generate
potent reactive oxygen species (ROS) that can damage cell DNA by
direct oxidation or by interfering with the mechanisms of DNA repair.ppearance during the ITT (kITT), (C) glycemic curve after glucose overload and (D) area
SG tumor and OTM, obese-MSG tumor metformin. Data are expressed as mean±SEM.
Fig. 5. Impact of obesity and metformin on tumor growth in vivo. Tumor development
was determined 15 days after injection of Walker-256 tumor cells. CT, control tumor;
CTM, control tumor metformin; OT, obese-MSG tumor and OTM, obese-MSG tumor
metformin. Data are expressed as mean±SEM. **pb0.001 vs CT, ***pb0.0001 vs CT and
#pb0.0001 vs OT. Numbers inside the bars represent the number of rats used.
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that may alter intracellular homeostasis favoring the accumulation of
mutations that, in turn, contribute to the multistage carcinogenesis
process (Cejas et al., 2004; Tabuchi et al., 2006; Valko et al., 2004).
Adipose cells found in greater quantity in tumor tissues of obese-
MSG rats also may have contributed to the increased tumor develop-
ment in this group. Adipose cells produce and release several factors,
such as leptin, IL-6 andTNF-alpha,which stimulate cell proliferation and
tumor angiogenesis (Hursting et al., 2007; Somasundar et al., 2004),
thus contributing to a bettermicroenvironment for tumor development.
The ﬁnding that metformin attenuated the tumor growth only in
the obese-MSG rats is intriguing. The reason is not easily explained,
but it is possible that the effect of this drug on tumor cells depends onfat tissue and on the metabolic abnormalities found in obesity (Algire
et al., 2008; Calle and Kaaks, 2004; Giovannucci and Michaud, 2007;
Jee et al., 2005).
The observed effect of metformin decreasing the tumor develop-
ment and the percentage of rats that developed tumors in obese-MSG
rats may be due, at least in part, to its metabolic effects correcting lipid
abnormalities, reducing accumulation of retroperitoneal and periepi-
didymal adipose tissues and decreasing lipid peroxidation rate.
Inhibition of lipolysis induced by metformin may be one of the
mechanisms involved in the correction of the lipid proﬁle reducing
plasma triglycerides and free fatty acids (Marchetti et al., 1988).
Another mechanism may involve AMPK activation (Zang et al., 2004).
Activation of this enzyme induces phosphorylation and consequent
inactivation of acetyl-CoA carboxylase (ACC) and 3-hydroxy-3-
methyl-glutaryl-CoA reductase (HMG-CoA reductase), contributing
to the reduction in fatty acid content and cholesterol and, conse-
quently, the synthesis of lipoproteins.
The lower number of rats that developed tumors in the OTM group
might also be explained by the reduction of the generation of ROS,
assessed indirectly by the lower rate of lipid peroxidation. Metformin,
owing to its antioxidant activity and to its effect decreasing the levels
of circulating triglycerides, may contribute to the lower generation of
ROS (Bellin et al., 2006; Cejas et al., 2004; Valko et al., 2004; Zhou
et al., 2007). In fact, previous data from our laboratory have shown the
lowering effect of metformin on the generation of ROS in mesenteric
arteries of obese-MSG rats without tumor (Lobato et al., 2010).
Another possible mechanism to explain the effect of metformin on
tumor growth is improving insulin sensitivity with consequent reduc-
tion of serum levels of this hormone. However, at least at the dose used
in this study, therewasno improvement in insulin sensitivity. Therefore,
this mechanism can be excluded. We may raise the possibility that the
effect of metformin on insulin sensitivity would be hampered by the
presence of tumor cells that also decrease insulin sensitivity in
peripheral tissues (Wals, 2010; Younes and Noguchi, 2000).
The fact that an increased necrotic area in tumor tissues was
observed in the metformin-treated groups might also explain the
reduction in tumor development in the obese rats. A direct effect of
metformin on the neoplastic cell or on the vascular tissue may be
leading to tumor necrosis and contributing to the decrease of tumor
development. In fact, it has been proposed by Sahra et al. (2008) that
metformin inhibits the proliferation of DU 145, PC-3 and LNCaP cancer
cells (prostate cancer cells), decreasing cell viability, as a consequence
of blocking cell cycle in G0/G1 and decreasing the levels of cyclin D1.
Therefore, metformin may have both an indirect effect correcting
metabolic abnormalities and a direct effect inhibiting proliferation of
neoplastic cells.
The presence of tumors in the body leads to several metabolic
changes that can lead to cachexia. It is known that themore aggressive
the tumor, the greater the cachexia index, which can worsen the
prognosis (Wals, 2010). One possible explanation for the greater
weight loss and the higher incidence of cachexia in the OT rats
compared to the CT rats (OT 90% vs CT 50%) might be the high amount
of energy consumed by the tumor cells, mainly in the form of glucose.
The glucose is converted to lactate by tumor cells during glycolysis, and
the lactate thus produced may be used by the liver as a gluconeogenic
precursor to synthesize glucose, which may be used by both the host
and the tumor (Inui, 2002; Younes andNoguchi, 2000). In this process,
there is greater energy expenditure because only twomolecules of ATP
are produced by glycolysis, whereas six molecules of ATP are utilized
to synthesize glucose from lactate. This contributes to the degradation
of the tissue as a result of the increased lipolysis and proteolysis aswell
as to weight and body mass loss leading to cachexia (Body, 1999;
Tisdale, 2001; Wals, 2010; Younes and Noguchi, 2000).
The fact that metformin failed to reduce the incidence of cachexia
and the greater weight loss in the OT rats can be explained by the
anorectic effect of the drug described previously (Haupt et al., 1991)
Fig. 6.Histologic analysis of tumor tissues bymeans of hematoxylin and eosin staining. (A) Necrotic area (arrows) and proliferative area present in tumor tissues of all groups. (B) Fat
cells (arrows) observed in greater quantity in the tumor tissue of obese rats. CT, control tumor; CTM, control tumor metformin; OT, obese-MSG tumor and OTM, obese-MSG tumor
metformin. n=10/group.
851E.A.I. Fonseca et al. / Life Sciences 88 (2011) 846–852and also detected in our study. Anorexia induced by metformin may
prevent the maintenance of body weight in rats with tumor and favor
the incidence of cachexia.
Conclusions
We demonstrated that obesity has an important role in tumor de-
velopment, increasing the tumor size and volume. We also demon-
strated that metformin, independent of improving insulin sensitivity,
was effective in controlling tumor development. This ﬁnding led us to
conclude that metformin has a direct and effective action on the tumor
cell, mainly by increasing the area of tumor necrosis. But an indirect
effect correcting lipid abnormalities, reducing the accumulation ofperiepididymal and retroperitoneal fat, and reducing lipid peroxidation
rate may also be contributing to its effect.
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